ADC Therapeutics SA
For the period ended Mar 13, 2024. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 13, 2024 · Filed Mar 13, 2024
Use the contents to explore the available documents and sections.
ADCT$1.58-3.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except for per share data)
(in thousands, except for per share data)
| For the three months ended December 31, | For the years ended December 31, | |||
|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |
| Revenue | ||||
| Product revenues, net | $16,643 | $19,798 | $69,060 | $74,908 |
| License revenues and royalties | 147 | 50,000 | 498 | 135,000 |
| Total revenue, net | 16,790 | 69,798 | 69,558 | 209,908 |
| Operating expense | ||||
| Cost of product sales | (1,215) | (320) | (2,529) | (3,301) |
| Research and development | (30,331) | (48,081) | (127,127) | (186,457) |
| Selling and marketing | (13,927) | (16,176) | (57,464) | (69,052) |
| General and administrative | (11,295) | (15,689) | (48,424) | (74,442) |
| Total operating expense | (56,768) | (80,266) | (235,544) | (333,252) |
| Loss from operations | (39,978) | (10,468) | (165,986) | (123,344) |
| Other income (expense) | ||||
| Interest income | 3,291 | 2,259 | 10,540 | 2,568 |
| Interest expense | (12,909) | (9,756) | (46,325) | (36,731) |
| Loss on debt extinguishment | — | — | — | (42,114) |
| Other, net | 9,724 | 1,211 | 6,352 | 52,804 |
| Total other income (expense) | 106 | (6,286) | (29,433) | (23,473) |
| Loss before income taxes | (39,872) | (16,754) | (195,419) | (146,817) |
| Income tax expense | (43,171) | (3,055) | (39,106) | (227) |
| Loss before equity in net losses of joint venture | (83,043) | (19,809) | (234,525) | (147,044) |
| Equity in net losses of joint venture | (1,988) | (3,535) | (5,528) | (10,084) |
| Net loss | $(85,031) | $(23,344) | $(240,053) | $(157,128) |
| Net loss per share | ||||
| Net loss per share, basic and diluted | $(1.03) | $(0.29) | $(2.94) | $(2.01) |
| Weighted average shares outstanding, basic and diluted | 82,292,594 | 80,463,306 | 81,712,166 | 78,152,964 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.